Putting Cancer's Secrets
In Plain Sight

We are developing novel anti-cancer therapies that work at the interface of the immune system and the tumor to target mechanisms that impact tumor growth and circumvent immune surveillance and tumor clearance.

 

Identifying ideal
cancer drug targets
is challenging

While hundreds of proteins are known to be preferentially upregulated by cancer, few have been identified to be expressed on a broad array of cancer types and even fewer are expressed evenly across the entire tumor. Only a scant few have been identified that are central to immune surveillance and tumor survival. These tumor-specific, immuno-active targets are Immuno-smart targets, and they are ideal cancer targets.

 
 

WHAT’S
POSSIBLE
NOW

There is untapped biology at the interface of the tumor and the immune system where mechanisms are at work that provide advantages for tumors to grow and circumvent immune surveillance and clearance.

 

In collaboration with the Lieping Chen lab at Yale, we have identified a novel class of Immuno-smart targets — tumor-specific, cell-surface proteins that are co-opted by cancer cells to drive local immune suppression. We are using these novel targets to develop a new generation of anti-cancer medicines, including therapeutic antibodies, bispecific antibodies, and payload-carrying biologics. NRM-823, our lead program, is a T cell engager directed against an Immuno-smart target and has recently entered clinical trials.

At Normunity, we are
identifying ideal cancer targets
THROUGH A NEW LENS

 About Us

We are a fusion of inspired minds

making the next advance in anti-cancer therapy.

Our innovation engine is built on an immersive academic-biotech partnership between the Lieping Chen lab at the Yale School of Medicine and Normunity, across two areas:

Platforms

Platforms from the ongoing partnership with the Lieping Chen lab interrogate interactions between cancer and the immune system to reveal previously unknown insights and mechanisms of cancer cell growth and capacity to circumvent immune surveillance and clearance.

 Our Science

Drug Discovery

Normunity is developing a pipeline of biologic medicines leveraging these targets, taking advantage of tumor specific characteristics and therapeutic opportunities across multiple biologic modalities.

Drug Discovery

 Our Pipeline

Our sights are set on new medicines to

help More patients

because we know there is unmet need in many solid tumors.

 

Your next career move is in plain sight.

Activate your hidden potential and join the Normunity team.

 Join us

 
 

NORMUNITY IN THE NEWS.

Normunity announces first patient dosed in Phase 1 clinical study of NRM 823, a T Cell Engager against a novel tumor-specific target, in patients with solid tumors
November 5, 2025
Back to Top